FBI approves QIAGEN’s NGS-based ForenSeq MainstAY workflow for the U.S. National DNA Index System (NDIS)
20 Junho 2023 - 5:05PM
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today
that the U.S. Federal Bureau of Investigation (FBI) has approved
its ForenSeq® MainstAY workflow. This allows accredited forensic
DNA laboratories to process DNA casework samples and search
resulting profiles against the U.S. National DNA Index System
(NDIS) CODIS database containing 20 million offender profiles and
used by authorities across the U.S. to help solve criminal
investigations nationwide.
The ForenSeq MainstAY workflow has been
developed and commercialized by Verogen, a QIAGEN company. It is
composed of the high-throughput ForenSeq MainstAY kit, the MiSeq
FGx Sequencing System and the ForenSeq MainstAY Analysis Module in
the Universal Analysis Software. The workflow was submitted for
NDIS approval by the Utah Bureau of Forensic Services Laboratory
System.
This standardized workflow supports volume
casework and sexual assault cases and is a cost-effective
alternative to analyzing short tandem repeats (STR) with capillary
electrophoresis (CE). Utilizing next-generation sequencing (NGS)
technology, it supports high-throughput processing of up to 96
samples in one run, provides improved sensitivity resulting in
increased profiling efficiency, higher resolution and is extensible
for applications such as forensic investigative genetic genealogy
(FIGG), phenotyping, and additional capabilities such as body fluid
identification.
“This approval by the FBI is a testament to the
high-quality NGS-based forensic products developed by Verogen”,
said Richard Price, Vice President and head of the HID and
Forensics business at QIAGEN. “ForenSeq MainstAY advances QIAGEN’s
commitment to deliver cost-competitive NGS workflows that allow
forensic laboratories to navigate the transition from capillary
electrophoresis without extending their budgets. NDIS compatibility
paves the way for the forensics community to begin this change and
provides them access to federal funding for validation and
implementation of NGS.”
Launched in 2021, the ForenSeq MainstAY workflow
targets 52 forensically relevant autosomal and Y-STR DNA markers
that support both identity confirmation and familial searching.
Optimized to overcome typical challenges faced by forensic
laboratories such as inhibitors, low levels of DNA input and
degradation, it meets CODIS and European standards, supporting
inter-database compatibility and the highest discrimination of any
commercially available STR kit. Furthermore, when used in
combination with the ForenSeq Kintelligence workflow, it supports
end-to-end forensic investigative genetic genealogy from lead
generation to identity verification. Importantly, it enables public
labs to solve more cases, identify the unidentified and exonerate
the innocent in accordance with forensic quality and accreditation
requirements.
The approval builds on the NDIS approval of the
MiSeq FGx Forensic Genomics System in 2019, encompassing the
ForenSeq DNA Signature Prep Kit workflow which allowed forensic
scientists to analyse up to 231 genomic DNA markers simultaneously,
supplying significantly more actionable data than commonly analysed
using older methods.
QIAGEN has a leading position in the human
identification and forensics market, having pioneered the
introduction of commercial DNA purification kits for forensic
casework samples in the late 1990s. Its comprehensive range of
solutions, including sample collection and preparation kits, DNA
profiling tools, and workflow automation products, are trusted by
forensic science laboratories and investigators worldwide. In early
2023, QIAGEN acquired Verogen, a leader in the use of NGS
technologies to further drive the future of human identification
and forensic investigation. Both companies had previously been
commercialization partners through a distribution agreement. This
acquisition has enabled QIAGEN to offer the most complete workflow
in the human identification and forensics market, solidifying its
leading position.
Learn more at:
https://www.qiagen.com/us/products/human-id-and-forensics/nextgeneration-sequencing/verogen-forenseq-mainstay-kit
Disclaimer: For forensics, human identification
or paternity/kinship use only. Not for use in diagnostic or
therapeutic applications.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding
company, is the leading global provider of Sample to Insight
solutions that enable customers to gain valuable molecular insights
from samples containing the building blocks of life. Our sample
technologies isolate and process DNA, RNA and proteins from blood,
tissue and other materials. Assay technologies make these
biomolecules visible and ready for analysis. Bioinformatics
software and knowledge bases interpret data to report relevant,
actionable insights. Automation solutions tie these together in
seamless and cost-effective workflows. QIAGEN provides solutions to
more than 500,000 customers around the world in Molecular
Diagnostics (human healthcare) and Life Sciences (academia, pharma
R&D and industrial applications, primarily forensics). As of
March 31, 2023, QIAGEN employed more than 6,200 people in over
35 locations worldwide. Further information can be found at
http://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press
release may be considered forward-looking statements within the
meaning of Section 27A of the U.S. Securities Act of 1933, as
amended, and Section 21E of the U.S. Securities Exchange Act of
1934, as amended. To the extent that any of the statements
contained herein relating to QIAGEN's products, including those
products used in the response to the COVID-19 pandemic, timing for
launch and development, marketing and/or regulatory approvals,
financial and operational outlook, growth and expansion,
collaborations, markets, strategy or operating results, including
without limitation its expected adjusted net sales and adjusted
diluted earnings results, are forward-looking, such statements are
based on current expectations and assumptions that involve a number
of uncertainties and risks. Such uncertainties and risks include,
but are not limited to, risks associated with management of growth
and international operations (including the effects of currency
fluctuations, regulatory processes and dependence on logistics),
variability of operating results and allocations between customer
classes, the commercial development of markets for our products to
customers in academia, pharma, applied testing and molecular
diagnostics; changing relationships with customers, suppliers and
strategic partners; competition; rapid or unexpected changes in
technologies; fluctuations in demand for QIAGEN's products
(including fluctuations due to general economic conditions, the
level and timing of customers' funding, budgets and other factors);
our ability to obtain regulatory approval of our products;
difficulties in successfully adapting QIAGEN's products to
integrated solutions and producing such products; the ability of
QIAGEN to identify and develop new products and to differentiate
and protect our products from competitors' products; market
acceptance of QIAGEN's new products and the integration of acquired
technologies and businesses; actions of governments, global or
regional economic developments, weather or transportation delays,
natural disasters, political or public health crises, including the
breadth and duration of the COVID-19 pandemic and its impact on the
demand for our products and other aspects of our business, or other
force majeure events; as well as the possibility that expected
benefits related to recent or pending acquisitions may not
materialize as expected; and the other factors discussed under the
heading “Risk Factors” contained in Item 3 of our most recent
Annual Report on Form 20-F. For further information, please refer
to the discussions in reports that QIAGEN has filed with, or
furnished to, the U.S. Securities and Exchange Commission.
Source: QIAGEN N.V.Category: Corporate
John Gilardi
QIAGEN N.V.
+49 2103 29 11711
ir@qiagen.com
Phoebe Loh
QIAGEN N.V.
+49 2103 29 11457
ir@qiagen.com
Thomas Theuringer
QIAGEN N.V.
+49 2103 29 11826
Daniela Eltrop
QIAGEN N.V.
+49 2103 29 11676
Qiagen NV (NYSE:QGEN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Qiagen NV (NYSE:QGEN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024